Haaß, Wiltrud <br/><br/>
The proteolytic activity of separase in BCR-ABL-positive cells is increased by imatinib.  [electronic resource] 

 -  PloS one  2012 
 - e42863 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1932-6203 
<br/><br/><label>Standard No.: </label>10.1371/journal.pone.0042863  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--pharmacology<br/>Benzamides<br/>Blast Crisis--drug therapy<br/>Cell Cycle Proteins--genetics<br/>Cyclin B1--genetics<br/>Drug Resistance, Neoplasm--drug effects<br/>Endopeptidases--genetics<br/>Fusion Proteins, bcr-abl--genetics<br/>Genomic Instability--drug effects<br/>HL-60 Cells<br/>Humans<br/>Imatinib Mesylate<br/>K562 Cells<br/>Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy<br/>Neoplasm Proteins--genetics<br/>Phosphorylation--drug effects<br/>Piperazines--pharmacology<br/>Protein Phosphatase 2--genetics<br/>Proteolysis<br/>Pyrimidines--pharmacology<br/>Securin<br/>Separase<br/>U937 Cells